CMPD News Just out. Current 29/32 Ask, allmost 3X Average daily Volume, Chart shows NO Overbought condition, up only 10% right now as the News just came out.
Good Luck to all !!!
Instock
CompuMed Performs Automated Bone Density Test With Under-$1000 Commercial Desktop
Scanner
Automated OsteoGram Software Works With Variety of Digital Inputs, Including Standard X-ray Films Digitized With
Commercial Desktop Scanners
MANHATTAN BEACH, Calif., April 28 /PRNewswire/ -- CompuMed, Inc. (Nasdaq: CMPD - news) announced today a breakthrough that will allow its proven
OsteoGram bone density test to be performed using low-cost commercially available desktop scanners, as well as a wide variety of other digital inputs, such as
digital x-ray machines and hospital and university teleradiology systems. The breakthrough technology builds upon the OsteoGram software originally developed by
CompuMed and licensed to Merck & Co., Inc. (NYSE: MRK - news). Effective March 31, 1998, CompuMed regained the worldwide exclusive rights to the
OsteoGram from Merck.
This new process will allow users to simply scan an x-ray film using a desktop scanner, apply automated bone density analysis software, and obtain a result
comparable to the previous OsteoGram process. That process had required x-ray films be mailed to a central laboratory, where they were analyzed utilizing
expensive liquid-cooled CCD cameras and trained technicians. The ability to use low-cost desktop scanners to digitize x-ray films and automatically produce
accurate bone density measurements has important implications for medical facilities in the United States and abroad that do not have ready access to specialized
bone densitometry equipment but do have ready access to standard x-ray equipment.
''Over 100,000 facilities in the U.S., and approximately 1 million facilities abroad already have standard x-ray equipment. An ordinary Pentium- type PC, an
inexpensive desktop scanner and our software may be all that will be required to perform the bone density tests needed by the millions of people throughout the
world who are at risk for osteoporosis and do not have access to specialized bone density testing equipment,'' said Jim Linesch, CompuMed President and CEO.
The software used to analyze the scanned or digitally acquired images measures the spatial and grayscale resolution of incoming image data, and makes the
necessary adjustments to the input signal in real time. The program is fully automated, requiring only a few simple steps prompted from a Windows 95 or NT-based
graphical user interface. Future versions of the program may support Sun workstations (used in many large hospital and university networks) and JAVA-based
Internet browser access.
The automated image processing and graphical user interface is being designed primarily for CompuMed's developmental Digital OsteoView 2000, the first device
with a software and hardware platform capable of detecting both osteoporosis and arthritis. That platform utilizes image data collected from an amorphous silicon flat
panel digital x-ray detector developed by Varian Associates, Inc. (NYSE: VAR - news) and Xerox Corporation (NYSE: XRX - news) under a grant from the U.S.
Defense Advanced Research Projects Agency (DARPA). CompuMed has worldwide exclusive rights to the Varian amorphous silicon technology in the fields of
appendicular bone mass measurement and computer-assisted arthritis detection. When CompuMed knew that it would regain exclusive rights to the OsteoGram, a
program was initiated to utilize innovations developed for the OsteoView to broaden the capabilities of the OsteoGram, allowing it to accept a variety of digital input
signals and perform automated bone density measurements.
CompuMed is concluding its internal testing with desktop scanners, conducting experiments on additional hardware platforms, and will soon launch a
university-based validation study of several implementations of its new ''platform independent'' bone density software. Some applications of this software may
require the Company to obtain marketing clearance from the U.S. Food and Drug Administration, although the OsteoGram itself has already received marketing
clearance by the FDA and is approved for reimbursement by Medicare.
CompuMed, based in Manhattan Beach, California, develops solutions to important medical problems through the use of computer technology. In addition to its
developmental Digital OsteoView 2000 bone density and arthritis testing device and its OsteoGram bone density testing software, CompuMed has developed
computer-aided telemedicine services for cardiology and currently provides on-line computer interpretation of electrocardiograms (ECGs) to physicians, government
and corporate healthcare providers.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product development and consumer demand and
acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions,
impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks. All such forward-looking statements whether
written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which
may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or
circumstances after the date hereof.
SOURCE: CompuMed, Inc. |
